Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELP-VEGF
- Development stage
- Preclinical
- Lead developer
- University of Mississippi Medical Center
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intra-arterial
01
Overview
ELP-VEGF is a recombinant fusion protein consisting of human vascular endothelial growth factor (VEGF) conjugated to an elastin-like polypeptide (ELP) drug-delivery vector. Developed by researchers at the University of Mississippi Medical Center and the University of Missouri, this therapeutic candidate utilizes the ELP platform—a thermally responsive biopolymer—to enhance the pharmacokinetic profile and organ-specific targeting of VEGF. The ELP tag increases the molecular weight to reduce renal clearance and can be engineered to provide sustained release or localized accumulation. ELP-VEGF is being investigated for its potential to treat cardio-renal syndromes, including chronic kidney disease (CKD) and heart failure with preserved ejection fraction (HFpEF), by stimulating angiogenesis, restoring microvascular density, and improving organ perfusion and function.
- Other names
- Elastin-like polypeptide-vascular endothelial growth factor fusion protein
02
Targets
sFlt-1 (Soluble VEGFR-1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on ELP-VEGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELP-VEGF.